Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ranitidine Compensation Programs Draw Complaints from Pharmacists, Separate Billing Seen “Unrealistic”
October 17, 2019
- Xofluza Filed in Japan for Post-Exposure Prophylaxis
October 17, 2019
- Asahi Kasei Initiates Voluntary Recall of Nafamostat after Glass Fragment Found in Vial
October 17, 2019
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
- Astellas to Sell 3 Asian Products to Daiichi Sankyo for 9.6 Billion Yen
October 16, 2019
- FDA OKs 1st Schizophrenia Patch Drug: Hisamitsu
October 16, 2019
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- No Major Drug Supply Disruption after Typhoon Hagibis
October 16, 2019
- Sakigake-Designated Radiation Therapy Agent Filed in Japan
October 16, 2019
- OrphanPacific to Take Over Marketing Authorization for MSD’s Diazoxide
October 16, 2019
- Sanofi, Kaken to Wind Up Clexane Partnership
October 16, 2019
- Eyes Turn to SGLT2 Inhibitors after Entresto’s Narrow Miss in HFpEF
October 16, 2019
- AZ, Sanofi Kick Off Japan PIII for RSV Prevention
October 15, 2019
- MSD Seeking to Trim 250 Jobs in Japan
October 15, 2019
- Japan Ethical Drug Market Forecast at 8.9 Trillion Yen in 2026: Fuji Keizai
October 15, 2019
- Shionogi Signs New Mycobacterial Deal with Hsiri
October 15, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- All Eyes on Performance of Top-2 Anti-Flu Drugs Xofluza, Inavir as Flu Seasons Approaches
October 11, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- AZ, Keio Univ. Pair Up to Create Real World Evidence in Healthcare
October 11, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…